Aggregate evidence quality: B; randomized controlled trials with limitations. . | |
---|---|
Benefit | Increase clinical cures, shorten illness duration, and may prevent suppurative complications in a high-risk patient population. |
Harm | Adverse effects of antibiotics. |
Cost | Direct cost of therapy. |
Benefits-harm assessment | Preponderance of benefit. |
Value judgments | Concern for morbidity and possible complications if untreated. |
Role of patient preference | Limited. |
Intentional vagueness | None. |
Exclusions | None. |
Strength | Strong recommendation. |
Aggregate evidence quality: B; randomized controlled trials with limitations. . | |
---|---|
Benefit | Increase clinical cures, shorten illness duration, and may prevent suppurative complications in a high-risk patient population. |
Harm | Adverse effects of antibiotics. |
Cost | Direct cost of therapy. |
Benefits-harm assessment | Preponderance of benefit. |
Value judgments | Concern for morbidity and possible complications if untreated. |
Role of patient preference | Limited. |
Intentional vagueness | None. |
Exclusions | None. |
Strength | Strong recommendation. |